QEL-002 (islet-targeted Foxp3-locked CAR-Treg therapy)

Overview

QEL-002 is an investigational, autologous, multi-modular engineered chimeric antigen receptor regulatory T-cell (CAR-Treg) therapy being developed by Quell Therapeutics (founded with King's College London, UCL, and Hannover Medical School Treg pioneers Giovanna Lombardi, Marc Martinez-Llordella, and Alberto Sanchez-Fueyo) in partnership with AstraZeneca.

First-generation adoptive Treg trials in Type 1 Diabetes — most notably the 113-patient Phase 2 Sanford T-Rex study (NCT02691247, covered under polyclonal-treg-therapy-t1d) — expanded polyclonal peripheral blood Tregs in which fewer than 0.1% of infused cells recognized pancreatic islet antigens, resulting in no preservation of C-peptide. Second-generation engineered Treg companies seek to solve three bottlenecks simultaneously:

1. Islet Homing & Antigen Specificity: Equipping Tregs with a synthetic chimeric antigen receptor (CAR) or engineered T-cell receptor (TCR) that recognizes beta-cell or pancreatic islet surface antigens so the infused cells accumulate in pancreatic islets and draining lymph nodes (PMID: 42307025, PMID: 41468096).
2. Phenotype Stability (Foxp3 Phenotype Lock): Natural CD4+ CD25+ CD127low Tregs can lose endogenous FOXP3 expression when exposed to high local concentrations of IL-1$\beta$, IL-6, and TNF-$\alpha$ inside inflamed islets, converting into pathogenic effector T cells. Quell's lentiviral vector co-delivers a constitutive Foxp3 Phenotype Lock cassette that locks the cell into a suppressive regulatory transcriptional state regardless of local inflammatory cytokines.
3. Bystander Suppression: Once activated by its target antigen in the islet microenvironment, a CAR-Treg suppresses neighboring autoreactive CD4+ and CD8+ T cells of any specificity (insulin, GAD65, IA-2, ZnT8) via IL-10, TGF-$\beta$, CTLA-4-mediated co-stimulation stripping, and IL-2 consumption, while patients maintain standard glucose management (70–180 mg/dL [3.9–10.0 mmol/L]).

Development Status & Critical Distinction Between QEL-002 (T1D), QEL-005 (CHILL), and Sonoma Biotherapeutics

1. Quell / AstraZeneca QEL-002 in Type 1 Diabetes (Preclinical, Option Exercised Nov 2024)

• In June 2023, AstraZeneca paid Quell $85 million upfront (with over $2 billion in potential development and commercial milestones) to co-develop multi-modular CAR-Treg therapies for Type 1 Diabetes and Inflammatory Bowel Disease.
• On November 18, 2024, Quell announced that AstraZeneca selected the lead Type 1 Diabetes candidate (QEL-002) and exercised its exclusive license option (triggering a $10 million milestone payment). Under the agreement, AstraZeneca assumed responsibility for IND/CTA-enabling preclinical toxicology, clinical trial execution, and commercialization, while Quell manufactures the clinical cell product for Phase 1/2 testing.
• As of October 2026, QEL-002 remains in IND/CTA-enabling preclinical development and has no registered human clinical trial on ClinicalTrials.gov.

2. Why QEL-005 (NCT07473154, CHILL Trial) Is Not a T1D Trial

• Secondary summaries occasionally conflate Quell's QEL-005 (NCT07473154, the Phase 1/2a CHILL basket trial recruiting in the UK, Germany, and Spain as of October 2026) with its T1D program.
• On ClinicalTrials.gov, NCT07473154 (QEL-005) is a CD19-targeted CAR-Treg study enrolling adults with diffuse cutaneous systemic sclerosis (dcSSc) and difficult-to-treat rheumatoid arthritis (D2TRA) — not Type 1 Diabetes. Alongside QEL-001 (NCT05234190, LIBERATE in liver transplantation), QEL-005 provides human platform safety and manufacturing experience for Quell's Foxp3-locked CAR-Treg vector, but contributes zero human T1D C-peptide data.

3. Peer Engineered-Treg Context: GentiBio (GNTI-122) and Sonoma Biotherapeutics (SBT-77-7101)

• GentiBio GNTI-122 (covered separately in gnti-122-engineered-tregs) is the only engineered Treg therapy that has entered a registered human T1D clinical trial to date (NCT06919393, FIERCE-T1D, dosing its first human participant in October 2025).
• Sonoma Biotherapeutics (co-founded by Jeffrey Bluestone, Fred Ramsdell, and Qizhi Tang) initially highlighted T1D in its foundational platform research, but its clinical CAR-Treg pipeline (SBT-77-7101, targeting citrullinated vimentin) is currently in Phase 1 trials for rheumatoid arthritis (NCT06201416) and hidradenitis suppurativa (NCT06361836), with no active clinical trial in Type 1 Diabetes.

Limitations & Watch Items

1. Zero Human T1D Data: Until AstraZeneca clears an IND/CTA and registers a first-in-human Phase 1 trial for QEL-002, its efficacy, islet trafficking, and safety in people with T1D remain entirely preclinical.
2. Autologous Manufacturing Complexity: Like oncology CAR-T therapies, autologous QEL-002 requires patient-specific leukapheresis, Treg isolation, lentiviral transduction, expansion, and release testing — a multi-week, high-cost supply chain compared with off-the-shelf biologics or nanoparticles.

Summary of Strengths & Limitations

Strengths

• Combines a tissue-targeted chimeric antigen receptor (CAR) with Quell's proprietary Foxp3 Phenotype Lock module to prevent engineered Tregs from converting into pro-inflammatory effector T cells inside inflamed pancreatic islets
• Backed by a major June 2023 AstraZeneca partnership ($85 million upfront, >$2 billion in potential milestones) in which AstraZeneca exercised its exclusive license option for the lead T1D candidate (QEL-002) in November 2024 ($10 million milestone) to lead clinical development
• Avoids the systemic failure mode of first-generation polyclonal Tregs (NCT02691247), where fewer than 0.1% of infused cells expressed islet-specific TCRs

Limitations

• Zero human clinical trials or human C-peptide data exist in Type 1 Diabetes as of October 2026 — QEL-002 remains in IND/CTA-enabling preclinical development
• Quell's active clinical trial QEL-005 (CHILL, NCT07473154) is a CD19 CAR-Treg basket trial in rheumatologic autoimmune diseases (systemic sclerosis and rheumatoid arthritis), not Type 1 Diabetes, and Sonoma Biotherapeutics' CAR-Treg clinical trials (SBT-77-7101) are likewise in rheumatoid arthritis and hidradenitis suppurativa rather than T1D
• Requires complex autologous leukapheresis, Treg sorting, lentiviral transduction, and custom GMP cell manufacturing, plus HLA compatibility for peptide-MHC-directed CAR modules